CDER Drug Approvals that Used Real-World Evidence

Why It Matters

RWE accelerates drug development by supplying credible evidence when randomized trials are impractical, expanding patient access and reducing development costs across the industry.

Key Takeaways

• FDA approved 13 drugs using RWE between 2021‑2025.
• RWE sources included medical records, registries, and expanded‑access programs.
• External control arms replaced traditional placebo groups for rare diseases.
• Retrospective cohort studies supported dosing‑regimen changes without new trials.
• RWE enabled supplemental NDAs for new indications, speeding patient access.

Pulse Analysis

The FDA’s 2018 Real‑World Evidence framework marked a turning point for regulators, encouraging the use of data gathered outside traditional clinical trials. By recognizing electronic health records, claims databases, and patient registries as valid sources, the agency aimed to lower barriers for innovative therapies, especially in populations where randomized studies are ethically or logistically challenging. This policy shift has spurred a cultural change within pharma, prompting sponsors to embed real‑world data collection early in development pipelines.

A review of CDER’s recent approvals shows how the guidance translates into practice. Thirteen products—ranging from acetylcysteine (Acetadote) to the rare‑disease agent Voxzogo—leveraged retrospective cohort designs, registry analyses, or externally controlled trials to satisfy the “substantial evidence of effectiveness” standard. Notably, external control arms derived from chart reviews or national registries replaced placebo groups for conditions such as hemophagocytic lymphohistiocytosis and Cushing’s syndrome, enabling faster label expansions and new molecular entity clearances. The diversity of data sources—medical records from Denmark, the SRTR transplant registry, and multinational expanded‑access programs—demonstrates the flexibility of RWE in addressing both safety and efficacy questions.

For the industry, the trend signals a strategic advantage: integrating real‑world data can shorten development timelines, reduce trial costs, and open pathways for niche indications that lack large patient pools. However, challenges remain, including data quality assurance, standardization across jurisdictions, and regulatory scrutiny of analytical methods. Companies that invest in robust data governance and transparent analytic plans are likely to reap the greatest benefits as the FDA continues to refine its evidentiary standards for future drug approvals.